Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse(®)

Passive therapy with neutralizing human monoclonal antibodies (mAbs) could be an effective therapy against severe acute respiratory syndrome coronavirus (SARS-CoV). Utilizing the human immunoglobulin transgenic mouse, XenoMouse®, we produced fully human SARS-CoV spike (S) protein specific antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales: Coughlin, Melissa, Lou, Gin, Martinez, Osvaldo, Masterman, Stephanie K., Olsen, Ole A., Moksa, Angelica A., Farzan, Michael, Babcook, John S., Prabhakar, Bellur S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2007
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103293/
https://www.ncbi.nlm.nih.gov/pubmed/17161858
http://dx.doi.org/10.1016/j.virol.2006.09.029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103293/
https://www.ncbi.nlm.nih.gov/pubmed/17161858
http://dx.doi.org/10.1016/j.virol.2006.09.029

Ejemplares similares